NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00069-0305-01 | 00069-0305 | Trastuzumab-qyyp | Trazimera | 420.0 mg/20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb. 24, 2020 | In Use | |
55513-0132-01 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | June 11, 2019 | In Use | |
00078-0495-61 | 00078-0495 | Aldesleukin | Proleukin | 1.1 mg/mL | Immunotherapy | Cytokine | Interleukin-2 | Intravenous | May 6, 1992 | Jan. 1, 2017 | No Longer Used |
00115-1476-23 | 00115-1476 | Imiquimod | Imiquimod | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb. 28, 2011 | June 1, 2017 | No Longer Used |
00115-1476-59 | 00115-1476 | Imiquimod | Imiquimod | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb. 28, 2011 | June 1, 2017 | No Longer Used |
00085-0539-01 | 00085-0539 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-0571-02 | 00085-0571 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-1110-01 | 00085-1110 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-1287-02 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1287-03 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1312-01 | 00085-1312 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1312-02 | 00085-1312 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Nov. 20, 2013 | No Longer Used | ||
00085-1388-01 | 00085-1388 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
00085-1388-02 | 00085-1388 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | March 29, 2011 | Jan. 13, 2016 | No Longer Used | ||
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov. 25, 2020 | In Use | |
74527-0022-02 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan. 15, 2021 | In Use | |
74527-0022-03 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan. 15, 2021 | In Use | |
00069-0238-01 | 00069-0238 | Rituximab-pvvr | Ruxience | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan. 23, 2020 | In Use | |
00069-0249-01 | 00069-0249 | Rituximab-pvvr | Ruxience | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan. 23, 2020 | In Use | |
00069-0315-01 | 00069-0315 | Bevacizumab-bvzr | Zirabev | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan. 13, 2020 | In Use | |
00069-0342-01 | 00069-0342 | Bevacizumab-bvzr | Zirabev | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan. 13, 2020 | In Use | |
73153-0900-01 | 73153-0900 | Lisocabtagene maraleucel | BREYANZI | Immunotherapy | CAR-T | CD19 | Feb. 5, 2021 | In Use | |||
00069-0308-01 | 00069-0308 | trastuzumab-qyyp | Trazimera | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | March 10, 2021 | In Use | |
72189-0084-24 | 72189-0084 | IMIQUIMOD | IMIQUIMOD | 12.5 mg/.25g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | March 23, 2020 | In Use | |
50242-0051-10 | 50242-0051 | Rituximab | Rituxan | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | June 3, 2019 | In Use |
Found 10,000 results in 4 milliseconds — Export these results